Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Age and Sex in Breast Cancer: Moving Beyond a One-Size-Fits-All Approach

Leone JP, Sedrak MS. Age and Sex in Breast Cancer: Moving Beyond a One-Size-Fits-All Approach. Clin Breast Cancer. 2026 Apr 14;26(5):71-74. doi: 10.1016/j.clbc.2026.03.015. Epub ahead[...]

A Delphi exercise informing the development of criteria to measure response to treatment in giant cell arteritis

Soowamber ML, Bond M, Sanchez-Alvarez C, Langford CA, Aydin SZ, Buttgereit F, Camellino D, Cid MC, Grayson PC, Hellmich B, Hendry A, Kermani TA, Khalidi[...]

DENND5B Disruption Results in Reduced Body Fat and Increased Intestinal Fatty Acid Oxidation by Activation of Autophagy

Neupane KR, Karakashian A, Mobilia M, Hage O, Tso P, Liu M, Vergnes L, Reue K, Gordon SM. DENND5B Disruption Results in Reduced Body Fat[...]